X4 Pharmaceuticals, Inc Net Income Loss

• X4 Pharmaceuticals, Inc showed a decrease of -111.5% in Net Income Loss from 2024 to 2025.
• This data is from X4 Pharmaceuticals, Inc's annual report (Form 10-K), filed with the SEC on March 17, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), X4 Pharmaceuticals, Inc's Net Income Loss has declined by 244.7%.
• Historical annual values: Fiscal year 2025: -$79.20 million | Fiscal year 2024: -$37.45 million | Fiscal year 2023: -$101.17 million | Fiscal year 2022: -$93.87 million | Fiscal year 2021: -$88.70 million | Fiscal year 2020: -$62.13 million | Fiscal year 2019: -$52.81 million | Fiscal year 2018: -$33.29 million | Fiscal year 2017: -$21.99 million | Fiscal year 2016: -$22.98 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026